桌面
添加运营动脉到电脑桌面
安装后将用独立窗口打开,并可在电脑桌面快捷访问
足迹
浏览记录
加载中...
查看更多

2026-美国中型生物制药:Summit Therapeutics股份有限公司:行业峰会:HARMONI6研究和ASCO年会展望,基准判断为整体生存趋势尚未达到统计显著性-50页

2026-美国中型生物制药:Summit Therapeutics股份有限公司:行业峰会:HARMONI6研究和ASCO年会展望,基准判断为整体生存趋势尚未达到统计显著性-50页 复制标题
2026-美国中型生物制药:Summit Therapeutics股份有限公司:行业峰会:HARMONI6研究和ASCO年会展望,基准判断为整体生存趋势尚未达到统计显著性-50页_第1页
1/52页
2026-美国中型生物制药:Summit Therapeutics股份有限公司:行业峰会:HARMONI6研究和ASCO年会展望,基准判断为整体生存趋势尚未达到统计显著性-50页_第2页
2/52页
2026-美国中型生物制药:Summit Therapeutics股份有限公司:行业峰会:HARMONI6研究和ASCO年会展望,基准判断为整体生存趋势尚未达到统计显著性-50页_第3页
3/52页
2026-美国中型生物制药:Summit Therapeutics股份有限公司:行业峰会:HARMONI6研究和ASCO年会展望,基准判断为整体生存趋势尚未达到统计显著性-50页_第4页
4/52页
2026-美国中型生物制药:Summit Therapeutics股份有限公司:行业峰会:HARMONI6研究和ASCO年会展望,基准判断为整体生存趋势尚未达到统计显著性-50页_第5页
5/52页
2026-美国中型生物制药:Summit Therapeutics股份有限公司:行业峰会:HARMONI6研究和ASCO年会展望,基准判断为整体生存趋势尚未达到统计显著性-50页_第6页
6/52页
2026-美国中型生物制药:Summit Therapeutics股份有限公司:行业峰会:HARMONI6研究和ASCO年会展望,基准判断为整体生存趋势尚未达到统计显著性-50页_第7页
7/52页
2026-美国中型生物制药:Summit Therapeutics股份有限公司:行业峰会:HARMONI6研究和ASCO年会展望,基准判断为整体生存趋势尚未达到统计显著性-50页_第8页
8/52页
2026-美国中型生物制药:Summit Therapeutics股份有限公司:行业峰会:HARMONI6研究和ASCO年会展望,基准判断为整体生存趋势尚未达到统计显著性-50页_第9页
9/52页
2026-美国中型生物制药:Summit Therapeutics股份有限公司:行业峰会:HARMONI6研究和ASCO年会展望,基准判断为整体生存趋势尚未达到统计显著性-50页_第10页
10/52页
26 May 2026US SMID-Cap BiopharmaceuticalsSummit Therapeutics Inc.RatingUnderperformPrice TargetSMMT7.70 USDJeffrey Walch+1 917 344 8613jeffrey.walch@bernsteinsg.comYi Zhao+1 917 344 8324yi.zhao@bernsteinsg.comReported EPSF25AF26EF27ESMMT (USD)(1.44)(0.96)(0.89)FinancialsF25AF26EF27ECAGREBITDA (M)(1,094)(768.02)(760.22)--Revenues (M)0211Valuation MetricsF25AF26EF27EReported P/E (x)(12.1)(18.2)(19.7)EV/Sales (x)N/MN/MSource: Bloomberg, Bernstein estimates and analysis.Summit: Counting down to the HARMONI6 ASCO plenary, ourbase case is non-statistically significant OS trendInvestment ImplicationsWe maintain an Underperform rating on SMMT. We recommend investors exit positions or,if possible, initiate short positions. In our opinion the long-term outlook for the company isnot on solid footing. Both SMMT and BioNTech have aggressively jumped into the misguided(based on our analysis) PD-L/VEGF bispecific experiment. This strategy could prove evenmore costly for SMMT than BioNTech because ivonescimab is their only drug in development.Unlike BNTX, SMMT has no on-market drugs, revenue or additional late-stage assets.We expect the key end-points for all three of SMMT’s ongoing Ph3 trials to read-out non-statistically significant: overall survival for HARMONi-3/-7 in NSCLC and PFS for HARMONi-GI3 in MSS colorectal cancer. There is an expansive history of failed registrational trialsinvestigating the combination of anti-PD-1+ anti-VEGF across tumor types. We discount thenarrative that “this time it’s different” for anti-PD-1+VEGF as lacking in supportive clinicaldata. Instead, we initiate with an Underperform rating because the science and clinical datatells us that history will repeat itself: encouraging PFS HR that degrades to negative OS and afailed clinical trial.We rate SMMT Underperform with PT $7.70 (-56%) based on our DCF valuation.Close Date 21 May 2026SMMT Close Price (USD) 17.47Price Target (USD) 7.70Upside/(Downside) (56)%52-Week Range 30.98/13.83SPX7,473.47FYE DecDiv Yield NAMarket Cap (USD) (M) 13,040EV (USD) (M) 12,347PerformanceYTD1M6M12MAbsolute (%)(3.9)(31.7)3.8(34.8)SPX (%)9.24.39.728.8Relative (%)(13.1)(36.0)(5.9)(63.6)Source: Bloomberg, Bernstein estimates and analysis.Price Performance, 1YR$35$30$25$20$1505/2508/2511/2502/2605/2660006500700075008000SMMTSPXSee the Disclosure Appendix of this report for required disclosures, analyst certifications and otherimportant information. Alternatively, visit our Global Research Disclosure Website.www.bernsteinresearch.comFirst Published: 26 May 2026 00:00 UTC Completion Date: 22 May 2026 16:47 UTC Jeffrey Walch +1 917 344 8613 jeffrey.walch@bernsteinsg.com26 May 2026DETAILSKey messages:1. We expect HARMONi6’s ASCO presentation to show non-statistically significant overall survival at interim analysis: OS trendHR >0.722 is likely in the absence of a pre-conference press release.2. HARMONi's pending FDA decision is a false catalyst: Toss-up for approval in a competitive patient po...

1、当您付费下载文档后,您只拥有了使用权限,并不意味着购买了版权,文档只能用于自身使用,不得用于其他商业用途(如 [转卖]进行直接盈利或[编辑后售卖]进行间接盈利)。
2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。
3、如文档内容存在违规,或者侵犯商业秘密、侵犯著作权等,请点击“违规举报”。

查找下载文件的指引

一、电脑端

- Windows 系统:按下键盘快捷键 `Ctrl + J`,即可打开下载列表。  

- Mac 系统:按下键盘快捷键 `⌘ + J`,即可打开下载列表。  

二、手机端

1. 打开手机浏览器,点击浏览器右下角的 “≡”(或“更多”)图标。  

2. 在弹出的菜单中找到并点击 “下载内容”(或类似选项),即可查看已下载的文件。  

提示:不同浏览器界面略有差异,若未找到“下载”入口,可尝试在浏览器设置中搜索“下载”关键词。


2026-美国中型生物制药:Summit Therapeutics股份有限公司:行业峰会:HARMONI6研究和ASCO年会展望,基准判断为整体生存趋势尚未达到统计显著性-50页

¥9.9
会员免费
下载本文档
安全支付  |  可重复下载
格式pdf
大小4.54 MB
页数约52页
下载12 次
报告魔方 + 关注
实名认证
确认删除?
会员
教程
联系
  • 站长微信
顶部